Patent 9234196 was granted and assigned to Alnylam Pharmaceuticals on January, 2016 by the United States Patent and Trademark Office.
The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a transthyretin (TTR) gene, and methods of using the dsRNA to inhibit expression of TTR.